相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Macrophages: Development and Tissue Specialization
Chen Varol et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Cindy Grandjenette et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2015)
The coming of age of engineered multivalent antibodies
Natalia Nunez-Prado et al.
DRUG DISCOVERY TODAY (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation
Yang Shen et al.
MABS (2015)
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Amita Datta-Mannan et al.
MABS (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Scavenger Receptor Structure and Function in Health and Disease
Izma Abdul Zani et al.
CELLS (2015)
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
Ronald P. Taylor et al.
BLOOD (2015)
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
Bing Li et al.
MABS (2014)
Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties
Edmund A. Rossi et al.
BIOCONJUGATE CHEMISTRY (2013)
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Brian Gurbaxani et al.
MOLECULAR IMMUNOLOGY (2013)
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
Paul J. Yazaki et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
The scavenger endothelial cell: a new player in homeostasis and immunity
Karen Kristine Sorensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
Rebecca Croasdale et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin et al.
CLINICAL CANCER RESEARCH (2012)
A strategy for risk mitigation of antibodies with fast clearance
Isidro Hoetzel et al.
MABS (2012)
FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study
Y. Zheng et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
Jianying Dong et al.
MABS (2011)
Engineering the variable region of therapeutic IgG antibodies
Tomoyuki Igawa et al.
MABS (2011)
Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species
Yulia Vugmeyster et al.
PHARMACEUTICAL RESEARCH (2011)
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2010)
Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys
Kay Stubenrauch et al.
DRUG METABOLISM AND DISPOSITION (2010)
Charge variants in IgG1 Isolation, characterization, in vitro binding properties and pharmacokinetics in rats
Leslie A. Khawli et al.
MABS (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
Edmund A. Rossi et al.
BLOOD (2009)
Monoclonal antibody clearance -: Impact of modulating the interaction of IgG with the neonatal Fc receptor
Amita Datta-Mannan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Humanized IgG(1) variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2007)
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life
B Gurbaxani et al.
MOLECULAR IMMUNOLOGY (2006)
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
JS Duffield et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and-2, and angiogenin during ovarian stimulation in non-human primates and women
TA Molskness et al.
HUMAN REPRODUCTION (2004)
Anti-CD95-induced lethality requires radioresistant FcγRII+ cells -: A novel mechanism for fulminant hepatic failure
S Jodo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity
JS Dela Cruz et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
